Get the Daily Brief
Latest Biotech News
CMS names drugs for Round‑Three negotiation: Part B biologics included
The U.S. Centers for Medicare & Medicaid Services published the 15 drugs selected for the third round of Medicare drug‑price negotiations, marking the first time Part B physician‑administered...
Eikon pushes public markets: dual IPO filings point to large raise for oncology push
Eikon Therapeutics advanced IPO plans with public filings indicating a multi‑hundred‑million dollar raise to fund its oncology‑focused pipeline anchored by Chinese cancer assets. The company set...
Moderna spins out late‑stage rare disease asset to Recordati: $50m upfront
Moderna out‑licensed a late‑stage rare‑disease candidate to Recordati in a deal that included $50 million up‑front consideration, shifting registrational‑stage development to the buyer. The...
Amgen walks away from Kyowa $400m autoimmune pact – program halted
Amgen terminated its collaboration with Kyowa Kirin on the anti‑OX40 antibody rocatinlimab, exiting a program for which it had previously paid $400 million in rights. Industry reports indicate...
FDA halts Regenxbio gene trials: tumor triggers safety pause
The FDA placed Regenxbio’s early-stage gene therapy trials on clinical hold after a treated pediatric patient was diagnosed with a central nervous system tumor. The regulator suspended studies of...
FDA grants AMT to NanoMosaic: gene therapy QC gets priority access
The FDA granted Advanced Manufacturing Technology (AMT) designation to NanoMosaic’s Tessie platform, a nanoneedle-based QC system for AAV gene therapies. The designation enables enhanced agency...
AstraZeneca doubles down on China: $15B plan and regional deals
AstraZeneca unveiled a long-term China strategy backed by a planned $15 billion investment to expand R&D and manufacturing across the value chain through 2030. The investment aims to scale cell...
Repertoire expands Big‑Pharma footprint: Lilly deal tops prior partnerships
Repertoire Immune Medicines added Eli Lilly to its roster of pharma partners in a multimarket tolerizing‑therapy collaboration, securing a major upfront and milestone package that values the...
Tenpoint wins FDA approval: dual‑agent presbyopia drop gets funding
Tenpoint Therapeutics won FDA approval for Yuvezzi, the first dual‑agent eye drop for adult presbyopia combining carbachol and brimonidine, and simultaneously closed financing commitments totaling...
Lilly bets on recombinase editing: Seamless tie could top $1.1B
Eli Lilly struck a global research and licensing agreement with Seamless Therapeutics to apply programmable recombinase gene editing to hearing loss targets, a deal with reported potential value...
Revita procedure cuts weight‑regain after GLP‑1s: 70% reduction
Fractyl Health reported six‑month data from the REMAIN‑1 randomized trial showing its Revita endoscopic procedure reduced post‑GLP‑1 weight regain by roughly 70% versus sham in patients who...
Moderna outlicenses rare‑disease asset: $50M upfront to Recordati
Moderna out‑licensed a late‑stage rare disease candidate to Recordati in a deal that provides $50 million upfront and transfers development responsibilities overseas. The asset could produce...
Eikon sets IPO terms: eyes $317M to advance oncology platform
Eikon Therapeutics filed to raise roughly $317 million in a Nasdaq IPO to accelerate its oncology protein‑dynamics platform and associated drug discovery pipeline. The company, founded by former...
Manufacturing surge: Cellares raises $257M; automaton funding follows
Cellares raised $257 million in a Series D round to accelerate global expansion of its clinical‑stage cell therapy manufacturing services and prepare for a 2027 IPO. The funding will support...
FDA halts Regenxbio AAV trials after patient tumor discovery
The U.S. Food and Drug Administration has placed two Regenxbio gene‑therapy trials on clinical hold after the identification of a brain tumor in a pediatric trial participant. Regenxbio’s programs...
Lilly bets $1.12B on recombinase editing — Seamless deal
Eli Lilly signed a global collaboration and license with Seamless Therapeutics to apply Seamless’s programmable recombinase platform to correct genetic causes of hearing loss. The pact includes up...
Repertoire adds Lilly in near‑$2B autoimmune decode deal
Repertoire Immune Medicines expanded its partner roster with Eli Lilly in a collaboration to develop tolerizing therapies for autoimmune diseases, securing an up‑front payment and potential...
FDA clears Tenpoint’s dual‑agent presbyopia drop; financing follows
Tenpoint Therapeutics won U.S. FDA approval for Yuvezzi, a carbachol‑brimonidine combination ophthalmic solution for adult presbyopia, marking the first dual‑agent drop approved for the...
FDA grants AMT to NanoMosaic — gene‑therapy QC gets regulatory lift
NanoMosaic received Advanced Manufacturing Technology (AMT) designation from the U.S. FDA for its Tessie platform, which quantifies vector genome integrity and capsid titers during AAV...
DeepMind’s AlphaGenome decodes noncoding DNA: variant effects in seconds
DeepMind published AlphaGenome, a long‑sequence DNA model that predicts regulatory activity and the effects of noncoding variants across up to one million base pairs. The Nature paper shows...